MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 599031 | Name: Lithospermic acid B
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lithospermic acid B, also known as salvianolic acid is isolated and purified from the crude extract of Salvia miltiorrhiza. Antioxidant activities Lithospermic acid B were also evaluated and the ABTS results showed that Lithospermic acid B exhibited high total antioxidant activities, its EC50 values were 1.43 0.01 .mu.g/mL.

Chemical Structure

Lithospermic acid B
CAS#121521-90-2

Theoretical Analysis

MedKoo Cat#: 599031

Name: Lithospermic acid B

CAS#: 121521-90-2

Chemical Formula: C36H30O16

Exact Mass: 718.1534

Molecular Weight: 718.62

Elemental Analysis: C, 60.17; H, 4.21; O, 35.62

Price and Availability

Size Price Availability Quantity
10mg USD 250.00 2 Weeks
25mg USD 450.00 2 Weeks
100mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Lithospermic acid B; Salvianolic acid B; Danfensuan B;
IUPAC/Chemical Name
2-(((2S,3S)-4-((E)-3-(1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-en-1-yl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carbonyl)oxy)-3-(3,4-dihydroxyphenyl)propanoic acid
InChi Key
SNKFFCBZYFGCQN-QUYNTYMASA-N
InChi Code
InChI=1S/C36H30O16/c37-20-6-1-16(11-24(20)41)13-27(34(45)46)50-29(44)10-5-18-3-9-23(40)33-30(18)31(32(52-33)19-4-8-22(39)26(43)15-19)36(49)51-28(35(47)48)14-17-2-7-21(38)25(42)12-17/h1-12,15,27-28,31-32,37-43H,13-14H2,(H,45,46)(H,47,48)/b10-5+/t27?,28?,31-,32+/m0/s1
SMILES Code
O=C([C@@H]1[C@@H](C2=CC=C(O)C(O)=C2)OC3=C(O)C=CC(/C=C/C(OC(C(O)=O)CC4=CC=C(O)C(O)=C4)=O)=C13)OC(C(O)=O)CC5=CC=C(O)C(O)=C5
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Salvianolic acid B is an active ingredient of Salvia miltiorrhiza, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication.
In vitro activity:
In vitro, Sal-B (salvianolic acid B) inhibited the proliferation and activation of inflammatory pathways in RAW264.7 cells. In addition, Sal-B had an inhibitory effect on nuclear factor of kappa light polypeptide gene enhancer in B cells (NF-κB) signalling. Reference: Aesthet Surg J. 2022 Dec 20:sjac334. https://pubmed.ncbi.nlm.nih.gov/36536993/
In vivo activity:
In CCl4-induced mouse liver fibrosis, intraperitoneal administration of SAB (salvianolic acid B) (30 mg · kg-1 · d-1, for 4 weeks) significantly alleviated hepatic fibrogenesis by inhibiting the activation of HSCs and collagen deposition. In addition, SAB displayed better anti-inflammatory effects in CCl4-induced liver fibrosis. Reference: Acta Pharmacol Sin. 2023 Jan 10. https://pubmed.ncbi.nlm.nih.gov/36627345/
Solvent mg/mL mM comments
Solubility
DMF 20.0 27.83
DMSO 48.3 67.26
Ethanol 55.0 76.54
PBS (pH 7.2) 1.0 1.39
Water 75.0 104.37
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 718.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Sun JM, Ho CK, Gao Y, Chong CH, Liu YD, Liu YX, Zheng DN, Zhang YF, Yu L. Salvianolic Acid B Reduces the Inflammation of Fat Grafts by Inhibiting the NF-Kb Signalling Pathway in Macrophages. Aesthet Surg J. 2022 Dec 20:sjac334. doi: 10.1093/asj/sjac334. Epub ahead of print. PMID: 36536993. 2. Zhang N, Hu Y, Ding C, Zeng W, Shan W, Fan H, Zhao Y, Shi X, Gao L, Xu T, Wang R, Gao D, Yao J. Salvianolic acid B protects against chronic alcoholic liver injury via SIRT1-mediated inhibition of CRP and ChREBP in rats. Toxicol Lett. 2017 Feb 5;267:1-10. doi: 10.1016/j.toxlet.2016.12.010. Epub 2016 Dec 15. PMID: 27989594. 3. Li ZB, Jiang L, Ni JD, Xu YH, Liu F, Liu WM, Wang SG, Liu ZQ, Wang CY. Salvianolic acid B suppresses hepatic fibrosis by inhibiting ceramide glucosyltransferase in hepatic stellate cells. Acta Pharmacol Sin. 2023 Jan 10. doi: 10.1038/s41401-022-01044-9. Epub ahead of print. PMID: 36627345. 4. Lin P, Qiu F, Wu M, Xu L, Huang D, Wang C, Yang X, Ye C. Salvianolic acid B attenuates tubulointerstitial fibrosis by inhibiting EZH2 to regulate the PTEN/Akt pathway. Pharm Biol. 2023 Dec;61(1):23-29. doi: 10.1080/13880209.2022.2148169. PMID: 36524761; PMCID: PMC9762854.
In vitro protocol:
1. Sun JM, Ho CK, Gao Y, Chong CH, Liu YD, Liu YX, Zheng DN, Zhang YF, Yu L. Salvianolic Acid B Reduces the Inflammation of Fat Grafts by Inhibiting the NF-Kb Signalling Pathway in Macrophages. Aesthet Surg J. 2022 Dec 20:sjac334. doi: 10.1093/asj/sjac334. Epub ahead of print. PMID: 36536993. 2. Zhang N, Hu Y, Ding C, Zeng W, Shan W, Fan H, Zhao Y, Shi X, Gao L, Xu T, Wang R, Gao D, Yao J. Salvianolic acid B protects against chronic alcoholic liver injury via SIRT1-mediated inhibition of CRP and ChREBP in rats. Toxicol Lett. 2017 Feb 5;267:1-10. doi: 10.1016/j.toxlet.2016.12.010. Epub 2016 Dec 15. PMID: 27989594.
In vivo protocol:
1. Li ZB, Jiang L, Ni JD, Xu YH, Liu F, Liu WM, Wang SG, Liu ZQ, Wang CY. Salvianolic acid B suppresses hepatic fibrosis by inhibiting ceramide glucosyltransferase in hepatic stellate cells. Acta Pharmacol Sin. 2023 Jan 10. doi: 10.1038/s41401-022-01044-9. Epub ahead of print. PMID: 36627345. 2. Lin P, Qiu F, Wu M, Xu L, Huang D, Wang C, Yang X, Ye C. Salvianolic acid B attenuates tubulointerstitial fibrosis by inhibiting EZH2 to regulate the PTEN/Akt pathway. Pharm Biol. 2023 Dec;61(1):23-29. doi: 10.1080/13880209.2022.2148169. PMID: 36524761; PMCID: PMC9762854.
1: Xiuli W, Wei G, Mao S. Pharmacokinetic investigation on interaction between hydrophilic lithospermic acid B and lipophilic tanshinone IIA in rats: an experi- mental study. J Tradit Chin Med. 2015 Apr;35(2):206-10. PubMed PMID: 25975054. 2: Murata T, Oyama K, Fujiyama M, Oobayashi B, Umehara K, Miyase T, Yoshizaki F. Diastereomers of lithospermic acid and lithospermic acid B from Monarda fistulosa and Lithospermum erythrorhizon. Fitoterapia. 2013 Dec;91:51-59. doi: 10.1016/j.fitote.2013.08.009. Epub 2013 Aug 23. PubMed PMID: 23978578. 3: Guo YX, Shi CZ, Zhang L, Lv L, Zhang YY. Extraction and isolation of lithospermic acid B from Salvia miltiorrhiza Bunge using aqueous two-phase extraction followed by high-performance liquid chromatography. J Sep Sci. 2016 Sep;39(18):3624-30. doi: 10.1002/jssc.201600368. Epub 2016 Sep 6. PubMed PMID: 27484287. 4: Lee BW, Chun SW, Kim SH, Lee Y, Kang ES, Cha BS, Lee HC. Lithospermic acid B protects β-cells from cytokine-induced apoptosis by alleviating apoptotic pathways and activating anti-apoptotic pathways of Nrf2-HO-1 and Sirt1. Toxicol Appl Pharmacol. 2011 Apr 1;252(1):47-54. doi: 10.1016/j.taap.2011.01.018. Epub 2011 Feb 2. PubMed PMID: 21295052. 5: Cho YH, Lim EY, Kim JM, Jung M, Lee HC, Seo M, Lee EJ. Nonmuscle myosin heavy chain and histone H3 are intracellular binding partners of lithospermic acid B and mediate its antiproliferative effect on VSMCs. Curr Med Chem. 2012;19(11):1731-7. PubMed PMID: 22257061. 6: Yamamoto H, Zhao P, Yazaki K, Inoue K. Regulation of lithospermic acid B and shikonin production in Lithospermum erythrorhizon cell suspension cultures. Chem Pharm Bull (Tokyo). 2002 Aug;50(8):1086-90. PubMed PMID: 12192141. 7: Watzke A, O'Malley SJ, Bergman RG, Ellman JA. Reassignment of the configuration of salvianolic acid B and establishment of its identity with lithospermic acid B. J Nat Prod. 2006 Aug;69(8):1231-3. PubMed PMID: 16933885. 8: Guo YX, Han J, Zhang DY, Wang LH, Zhou LL. An ammonium sulfate/ethanol aqueous two-phase system combined with ultrasonication for the separation and purification of lithospermic acid B from Salvia miltiorrhiza Bunge. Ultrason Sonochem. 2012 Jul;19(4):719-24. doi: 10.1016/j.ultsonch.2011.12.017. Epub 2012 Jan 3. PubMed PMID: 22265019. 9: Guo YX, Zhou LL, Li T, Wang LH. Preparative separation of lithospermic acid B from Salvia miltiorrhiza by polyamide resin and preparative high-performance liquid chromatography. J Chromatogr A. 2011 Jul 22;1218(29):4606-11. doi: 10.1016/j.chroma.2011.05.048. Epub 2011 May 20. PubMed PMID: 21652037. 10: Cui L, Chan W, Wu JL, Jiang ZH, Chan K, Cai Z. High performance liquid chromatography-mass spectrometry analysis for rat metabolism and pharmacokinetic studies of lithospermic acid B from danshen. Talanta. 2008 May 30;75(4):1002-7. doi: 10.1016/j.talanta.2007.12.045. Epub 2008 Jan 15. PubMed PMID: 18585175. 11: Kang ES, Lee GT, Kim BS, Kim CH, Seo GH, Han SJ, Hur KY, Ahn CW, Ha H, Jung M, Ahn YS, Cha BS, Lee HC. Lithospermic acid B ameliorates the development of diabetic nephropathy in OLETF rats. Eur J Pharmacol. 2008 Jan 28;579(1-3):418-25. Epub 2007 Nov 1. PubMed PMID: 18031723. 12: Kang DG, Oh H, Sohn EJ, Hur TY, Lee KC, Kim KJ, Kim TY, Lee HS. Lithospermic acid B isolated from Salvia miltiorrhiza ameliorates ischemia/reperfusion-induced renal injury in rats. Life Sci. 2004 Aug 27;75(15):1801-16. PubMed PMID: 15302225. 13: Kim HH, Kim J, Ji HY, Kim YC, Sohn DH, Lee BM, Lee HS. Pharmacokinetics of lithospermic acid B isolated from Salvia miltiorrhiza in rats. J Toxicol Environ Health A. 2005 Dec 10;68(23-24):2239-47. PubMed PMID: 16326437. 14: Kang DG, Oh H, Chung HT, Lee HS. Inhibition of angiotensin converting enzyme by lithospermic acid B isolated from Radix Salviae miltiorrhiza Bunge. Phytother Res. 2003 Sep;17(8):917-20. PubMed PMID: 13680824. 15: Kamata K, Noguchi M, Nagai M. Hypotensive effects of lithospermic acid B isolated from the extract of Salviae miltiorrhizae Radix in the rat. Gen Pharmacol. 1994 Jan;25(1):69-73. PubMed PMID: 8026714. 16: Xiao Y, Gao S, Di P, Chen J, Chen W, Zhang L. Lithospermic acid B is more responsive to silver ions (Ag+) than rosmarinic acid in Salvia miltiorrhiza hairy root cultures. Biosci Rep. 2009 Oct 6;30(1):33-40. doi: 10.1042/BSR20080124. PubMed PMID: 19210264. 17: Guo YX, Zhang DJ, Wang H, Xiu ZL, Wang LX, Xiao HB. Hydrolytic kinetics of lithospermic acid B extracted from roots of Salvia miltiorrhiza. J Pharm Biomed Anal. 2007 Jan 17;43(2):435-9. Epub 2006 Sep 6. PubMed PMID: 16950588. 18: Fung KP, Wu J, Zeng LH, Wong HN, Lee CM, Hon PM, Chang HM, Wu TW. Lithospermic acid B as an antioxidant-based protector of cultured ventricular myocytes and aortic endothelial cells of rabbits. Life Sci. 1993;53(12):PL189-93. PubMed PMID: 8395629. 19: Guo YX, Xiu ZL, Zhang DJ, Wang H, Wang LX, Xiao HB. Kinetics and mechanism of degradation of lithospermic acid B in aqueous solution. J Pharm Biomed Anal. 2007 Mar 12;43(4):1249-55. Epub 2006 Nov 21. PubMed PMID: 17118607. 20: Li X, Yu C, Wang L, Lu Y, Wang W, Xuan L, Wang Y. Simultaneous determination of lithospermic acid B and its three metabolites by liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal. 2007 Apr 11;43(5):1864-8. Epub 2007 Jan 9. PubMed PMID: 17275241.